Beacon Biosignals, a neurotechnology company pioneering AI-driven diagnostics for brain health, has raised $86 million in a Series B funding round, bringing its total funding to over $121 million. The oversubscribed round was led by Innoviva, Google Ventures (GV), Nexus NeuroTech Ventures, S32, Catalio Capital Management, and Takeda, with continued backing from General Catalyst, Logos Capital, Casdin Capital, and Indicator Ventures. The investment will fuel the expansion of Beacon’s precision medicine data platform, aimed at building the world’s largest neurodiagnostic dataset. The company is focused on accelerating the discovery and development of treatments for neurological and psychiatric disorders by leveraging AI to analyze real-world brain data collected during sleep. Beacon’s core technology, the Beacon Platform, combines clinically validated EEG data with advanced artificial intelligence to generate objective, quantitative biomarkers of brain function. Sleep, a critical but underutilized window into brain health, serves as a key diagnostic and research tool for conditions such as clinical depression, Parkinson’s disease, Alzheimer’s disease, and sleep apnea. The company has already established partnerships with more than half of the world’s top ten biopharmaceutical companies, as well as a growing number of leading biotechs. These collaborations use Beacon’s AI-derived biomarkers to improve drug development, enabling more precise patient selection, providing reliable clinical endpoints, and helping close gaps in care for brain disorders. The Series B follows Beacon’s recent acquisition of CleveMed’s home sleep-testing (HST) technology, which expanded the Beacon Platform to include airflow, respiratory effort, and oxygen saturation data. This integration creates a comprehensive, clinically integrated system for measuring both brain and cardiopulmonary function at home—offering the same clinical-grade insights as traditional in-lab sleep studies but with lower cost and greater patient convenience. Beacon’s FDA-cleared wearable devices, the Beacon Waveband and SleepView, allow for high-quality, real-world sleep monitoring without the need for a sleep lab. Unlike consumer sleep trackers that rely on heart rate and movement, Beacon’s system captures true EEG and cardiopulmonary data, delivering gold-standard clinical information. The company’s approach is gaining recognition from industry leaders. Anthony Philippakis, MD, PhD, General Partner at GV, said Beacon is bringing the same level of precision to brain health that has transformed other areas of medicine. Pavel Raifeld, CEO of Innoviva, praised the company for building a foundational infrastructure for precision neuroscience. By combining sleep EEG with home-based cardiopulmonary monitoring, Beacon is creating a powerful toolkit for both research and clinical care. The data generated helps identify early disease markers, assess drug effects, and support the development of targeted therapies. Beacon Biosignals is at the forefront of a new era in neuroscience, using real-world data and AI to turn sleep into a window for understanding and improving brain health.